Watch LFCR. Know when insiders buy.
One email the day a filing lands. Free.
LFCR
LIFECORE BIOMEDICAL, INC.
6.37
+0.00 +0.00%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
FINANCIALS: NOT YET PULLED FROM SEC XBRL, CHECK BACK AFTER TONIGHT52W 3.66 – 8.82
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q 2027 · Jun 30 | — | — | — | $2.6M | −$6.2M | — | -0.19 | −$2.2M | $513K | −$2.7M | Aug 5 |
| Q3 2026 · Mar 31 | — | — | — | −$4.7M | −$15M | — | -0.43 | $4.7M | $1.1M | $3.6M | May 6 |
| Q1 2026 · Sep 30 | — | — | — | −$3.1M | −$10M | — | -0.29 | $1.8M | $1.7M | $25K | Nov 6 |
| Q4 2025 · May 25 | — | — | — | $5.3M | −$1.1M | — | -0.06 | $5.3M | $2.1M | $3.3M | Aug 5 |
| Q3 2025 · Feb 23 | — | — | — | −$9M | −$14.8M | −194.5% | -0.42 | $1.2M | $5.5M | −$4.3M | May 6 |
| Q2 2025 · Nov 24 | — | — | — | −$2M | −$6.6M | −146.2% | -0.25 | −$6.1M | $2.4M | −$8.6M | Jan 2 |
| Q1 2025 · Aug 25 | — | — | — | −$11.6M | −$16.2M | — | -0.53 | −$613K | $3.4M | −$4M | Nov 6 |
| Q4 2024 · May 26derived | — | — | — | $2.1M | −$7.1M | — | -0.19 | $8.7M | $2.7M | $6M | Mar 16 |
| Q3 2024 · Feb 25 | — | — | — | −$895K | $15.6M | — | 0.42 | −$1.4M | $6.4M | −$7.8M | Apr 3 |
| Q2 2024 · Nov 26 | — | — | — | −$1.5M | $14.2M | — | 0.39 | $1.3M | $4.3M | −$3M | Jan 2 |
| Q1 2024 · Aug 27 | — | — | — | −$8.6M | −$10.8M | — | -0.35 | −$8.3M | $5.1M | −$13.4M | Jan 2 |
| Q4 2023 · May 28 | — | — | — | −$6.6M | −$39.3M | — | -1.32 | −$2.3M | — | — | Aug 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to May 25 | — | — | −$17.2M | −$38.7M | — | -1.27 | −$206K | $13.4M | −$13.6M | — | — |
| FY2024 · to May 26 | — | — | −$8.8M | $12M | — | 0.33 | $257K | $18.4M | −$18.1M | — | — |
| FY2023 · to May 28 | — | — | −$21.8M | −$99.6M | — | -3.32 | −$17.4M | — | — | — | — |
| FY2022 · to May 29 | — | — | −$11.8M | −$116.7M | — | -3.97 | −$22.6M | $26.2M | −$48.8M | — | — |
| FY2021 · to May 30 | — | — | −$8.8M | −$32.3M | — | -1.10 | $16.5M | $19.3M | −$2.8M | — | — |
| FY2020 · to May 31 | — | — | −$25.9M | −$38.2M | — | -1.31 | −$17M | $12.2M | −$29.3M | — | — |
Every number comes from LIFECORE BIOMEDICAL, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.